Galenvs Sciences

September 5, 2024

Galenus Sciences

Galenvs is a specialized precision developer & manufacturer of DNA/RNA oligonucleotides for therapeutics, offering services from proof-of-concept through in vitro validation and pilot-scale production.

This includes ASO, SSO, PMO, siRNA, sgRNA design and synthesis – as well as chemical modifications for enhanced stability and cellular uptake.

Industry news

Médicament Québec Awards Two Major Grants for RNA Innovation with Financial Support from the Ministère de l’Économie, de l’Innovation et de l’Énergie (MEIE)

AReNA shines at BIO 2025

Eli Lilly and Company to Acquire Verve Therapeutics for Up to $1.3 Billion

Membres de l'équipe AReNA

AReNA sponsors Rendez-vous Québec at the launch of the BIO International Convention

Pharmaceutiques Magazine spotlights Quebec, driving force for North America’s RNA Sector

DirectIndustry’s take on AReNA, Quebec’s Ambitious Plan to Become a Global RNA Therapeutics Leader

MedicalExpo E-Magazine article highlights AReNA’s panelists at 2025 EFFERVESCENCE on RNA Therapies: From Pandemic Vaccines to Tomorrow’s Medicine.

D2R et AReNA put RNA experts forward at the 92nd ACFAS Congress

effervescence conference 2025

AReNA’s expert panel and networking breakfast energize EFFERVESCENCE conference in Montreal

Panagitos Prinos - Takis photo

Panagiotis Prinos appointed as Director of Réseau DePTAQ

The AReNA breakfast series presents the CELLULE and the RNA valorisation and entrepreneurship team.

CASTL and the DePTAQ Network present their initiative during AReNA’s breakfast event at IRCM

Jean-Pierre Perrault elu recteur de l'UdeS

Jean-Pierre Perreault is elected as Rector of Université de Sherbrooke

Two panelists represent AReNA at Leyton Connect’s 5-to-7

December 19, 2024

AReNA attended FISQ

December 19, 2024

AReNA attends CASTL’s Open Door Day

November 15, 2024

Epitopea closes their $31 million pre-Series A financing.

October 21, 2024

Congratulations to the Nobel Prize winners in Medicine!

September 19, 2024

Congratulations to the 23 recipients of the D2R funding programs

The creation of training programs to meet the needs of the RNA therapeutics industry

The creation of a biomanufacturing services platform to boost expertise in Quebec and accelerate the development of RNA therapies

A new initiative to stimulate innovation and entrepreneurship in the RNA therapy sector in Quebec

Quebec Launches AReNA to Become a Global Leader in RNA Therapies

A group of partners are launching the CELLULE to accelerate the development of RNA therapies in Quebec

The long-overlooked molecule that will define a generation of science